Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J06BC03
|
| gptkbp:CASNumber |
300832-84-2
|
| gptkbp:developedBy |
gptkb:Human_Genome_Sciences
|
| https://www.w3.org/2000/01/rdf-schema#label |
Raxibacumab
|
| gptkbp:indication |
prophylaxis of inhalational anthrax
treatment of inhalational anthrax in combination with antibiotics |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG1 kappa monoclonal antibody
|
| gptkbp:marketedAs |
GlaxoSmithKline
|
| gptkbp:mechanismOfAction |
neutralizes anthrax toxin
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:synonym |
gptkb:ABthrax
|
| gptkbp:target |
gptkb:protective_antigen_of_Bacillus_anthracis
|
| gptkbp:UNII |
6T6J2J95HK
|
| gptkbp:usedFor |
treatment of inhalational anthrax
|
| gptkbp:bfsParent |
gptkb:Emergent_BioSolutions
|
| gptkbp:bfsLayer |
5
|